IRWD Stock — Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. (IRWD)

Updated October 16, 2026.

IRWD is a Stock. Total return is -64.1% over the past 16.7 years, 897.6 points behind SPY at 833.5%.

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases, with its primary commercial product being linaclotide (marketed as LINZESS and CONSTELLA) for constipation and irritable bowel syndrome, alongside a pipeline of experimental treatments for visceral pain conditions and short bowel syndrome developed through partnerships with major pharmaceutical companies including AbbVie, AstraZeneca, and Astellas Pharma. The company does not currently pay distributions to shareholders. Ironwood appeals to investors seeking exposure to specialized pharmaceutical development rather than current income.

IRWD performance versus SPY

Price and return data through 2026-10-16.

Total return is -64.1% over the past 16.7 years, 897.6 points behind SPY at 833.5%. Over the past year its total return — price change plus distributions reinvested — is 125.8%. Its deepest 1-year drawdown was 43.6%.

IRWD key facts

Asset type

Stock

Asset class

Equity

Inception date

02/03/2010

Distribution frequency

None

Last close

$3.50 (as of 2026-10-16)

Market cap

$578,339,814

Average volume

2530654.0

Beta

0.22

Payout ratio

0.0%

P/E ratio

4.55

Forward P/E

12.3305

EPS

$0.77

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

IRWD risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 43.6%.

Who may consider IRWD — and who may not

It is a weaker fit for investors who need monthly cash flow (IRWD does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on IRWD

• All tickers starting with I

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions